Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine + Streptozocin +/- Cisplatin in Neuroendocrine Tumors
NCT00602082Phase 2Completed
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Start
- Aug 2005
- Primary completion
- Dec 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cisplatin in neuroendocrine tumors (NETs) (2 arms), sponsored by Cambridge University Hospitals NHS Foundation Trust. Primary endpoint: Objective Response Rate. Started Aug 2005; status: completed.
02
Drugs
cisplatin
03
Conditions
neuroendocrine tumors (NETs)
Beyond the preview
Go deeper on NCT00602082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00602082.